New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
17:08 EDTBDSI, ENDPBioDelivery Sciences reports cash at end of FY12 $63.2M vs. $10.8M
BioDelivery Sciences (BDSI) ,BDSI's, research and development expenditures increased from $20.8M in 2011 to $35.4M in 2012. Revenues recognized in 2012 were $54.5M, including $35.8M from Endo (ENDP) and $17.5M previously deferred revenue associated with the BDSI commercialization agreement with Meda for BDSI's FDA approved product ONSOLIS. At the end of 2012, BDSI had $9.2M in deferred revenue associated with Endo, which will be recognized through 2013 and into early 2014 as clinical trials progress. BDSI reported net income of $1.7M or 5c per share for the twelve months ending December 31. That compares to a net loss of $23.3M or (82c) per share in 2011. At the end of 2012, BDSI had $63.2M in cash compared to $10.8M at December 31, 2011.
News For BDSI;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 20, 2015
08:09 EDTENDPBioSpecifics announces approval of Xiaflex in Japan
Subscribe for More Information
July 17, 2015
10:05 EDTENDPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:38 EDTENDPLeerink puts 25% odds on Teva, Mylan deal within 12 months
Subscribe for More Information
06:43 EDTENDPEndo upgraded to Top Pick from Outperform at RBC Capital
Subscribe for More Information
July 16, 2015
11:36 EDTBDSIBioDelivery Sciences management to meet with FBR Capital
Meetings to be held in Minneapolis on July 22 and in Dallas on July 23 hosted by FBR Capital.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use